Bruker Corporation (FRA:BKD)
Germany
· Delayed Price · Currency is EUR 41.23
+0.49 (1.20%)
At close: Dec 5, 2025
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| United States Revenue | 927.30M | 938.50M |
Log In |
Log In |
Log In | Upgrade
|
| Germany Revenue | 277.60M | 310.70M |
Log In |
Log In |
Log In | Upgrade
|
| Rest of Europe Revenue | 965.70M | 873.00M |
Log In |
Log In |
Log In | Upgrade
|
| China Revenue | 451.50M | 471.20M |
Log In |
Log In |
Log In | Upgrade
|
| Rest of Asia Pacific Revenue | 553.70M | 518.50M |
Log In |
Log In |
Log In | Upgrade
|
| Total Asia Pacific Revenue | 1.01B | 989.70M |
Log In |
Log In |
Log In | Upgrade
|
| Other Countries Revenue | 263.10M | 254.50M |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Total) | 3.44B | 3.37B |
Log In |
Log In |
Log In | Upgrade
|
Revenue
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| BSI BioSpin Revenue | 884.20M | 905.70M |
Log In |
Log In |
Log In | Upgrade
|
| BSI CALID Revenue | 1.20B | 1.09B |
Log In |
Log In |
Log In | Upgrade
|
| BSI Life Science Revenue | 2.08B | 2.00B |
Log In |
Log In |
Log In | Upgrade
|
| BSI Nano Revenue | 1.09B | 1.10B |
Log In |
Log In |
Log In | Upgrade
|
| Total BSI Revenue | 3.18B | 3.10B |
Log In |
Log In |
Log In | Upgrade
|
| BEST Revenue | 271.50M | 283.00M |
Log In |
Log In |
Log In | Upgrade
|
| Eliminations from Revenue | -9.50M | -14.10M |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Other) | -3.18B | -3.10B |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Total) | 3.44B | 3.37B |
Log In |
Log In |
Log In | Upgrade
|
EBIT
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| BSI BioSpin Operating Income | 90.70M | 157.80M |
Log In |
Log In |
Log In | Upgrade
|
| BSI CALID Operating Income | 180.20M | 180.00M |
Log In |
Log In |
Log In | Upgrade
|
| BSI Life Science Operating Income | 270.90M | 337.80M |
Log In |
Log In |
Log In | Upgrade
|
| BSI Nano Operating Income | -100.10M | 2.30M |
Log In |
Log In |
Log In | Upgrade
|
| Corporate, Eliminations and Other Operating Income | -134.10M | -121.90M |
Log In |
Log In |
Log In | Upgrade
|
| Total BSI Operating Income | 36.65M | 218.20M |
Log In |
Log In |
Log In | Upgrade
|
| BEST Operating Income | 27.30M | 34.90M |
Log In |
Log In |
Log In | Upgrade
|
| Operating Income (Other) | 59.85M | -218.20M |
Log In |
Log In |
Log In | Upgrade
|
| Operating Income (Total) | 160.50M | 253.10M |
Log In |
Log In |
Log In | Upgrade
|
Capital Expenditures
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2012 - 2019 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2012 - 2019 |
| BSI BioSpin Capital Expenditures | 22.80M |
Log In |
Log In |
Log In | Upgrade
|
| BSI CALID Capital Expenditures | 34.10M |
Log In |
Log In |
Log In | Upgrade
|
| BSI Life Science Capital Expenditures | 56.90M |
Log In |
Log In |
Log In | Upgrade
|
| BSI Nano Capital Expenditures | 19.30M |
Log In |
Log In |
Log In | Upgrade
|
| Corporate Capital Expenditures | 14.80M |
Log In |
Log In |
Log In | Upgrade
|
| Total BSI Capital Expenditures | 91.00M |
Log In |
Log In |
Log In | Upgrade
|
| BEST Capital Expenditures | 24.30M |
Log In |
Log In |
Log In | Upgrade
|